{"id":"tp-47297","type":"article-newspaper","title":"Neurocrine Expects INGREZZA Revenue Growth in 2027 on Volume Gains","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/47297","datePublished":"2026-11-03T04:33:56.000Z","dateModified":"2026-11-03T04:33:56.000Z","language":"en","abstract":"Chief Financial Officer Matthew Abernethy expects double-digit volume growth to outweigh pricing pressure. Formal 2027 sales guidance is due in February.","section":"Business","references":[]}